Conference Day One - Wednesday, 9 April
8:00 am Registration & Morning Coffee
8:55 am Chair’s Opening Remarks
Choosing The Right Model to Maximise Translational Success
9:00 am Plenary Panel: How Do You Select the Best Model for Your Study & Achieve the Best Balance of Preclinical Tumour Models?
Synopsis
- Unveiling how integrating multiple tumour models can enhance predictive accuracy and improve translational relevance
- Uncovering actionable insights into streamlining tumour model research amidst increasing financial and logistical pressure
- Addressing the critical need for next-generation tumour models that better mimic clinical outcomes, accelerating the path to successful therapies
9:45 am Advancing Oncology Research with Mouse Models: Applications & Limitations
Synopsis
- Comparing different mouse models (syngeneic, CDX and humanised) to highlight their roles in immuno-oncology research
- Demonstrating anti-tumour efficacy through case studies on IL-15 cytokine-based compounds and combination therapies
- Addressing limitations in a range of models and proposing strategies to enhance translatability
10:15 am Preclinical Insights into Evaluating Therapeutic Vaccines for HPV: Tumour Models, Immune Responses, & Translational Tools
Synopsis
- Evaluating HPV+ tumour models, highlighting the challenges and opportunities in using inbred vs. outbred mice to study therapeutic vaccines
- Discussing insights from an HPV infection model in NHPs to better understand vaccine performance and immune dynamics
- Outlining the development of an ex vivo assay to simulate vaccination and assess cancer-killing performance of T cells in a translational context
10:45 am Speed Networking
Synopsis
Be part of this landmark moment as the Nordic tumour models community comes together for the first time. Our fast-paced, 3-minute introductions are designed to maximise your networking potential, helping you meet like-minded innovators and build connections that could shape the future of oncology research!
11:15 am Morning Break & Networking
Unlocking Strategies to Advance Cancer Immunotherapies: Tackling Immune Resistance with Tumour Models
11:45 am Exploring SLAMF6 as a Novel Target in Cancer Immunotherapy
Synopsis
- Revealing SLAMF6 upregulation in cancer models as a new immune escape mechanism, advancing our understanding of tumour immune evasion
- Demonstrating SLAMF6 modulation in preclinical models and its critical role in protecting cancer cells from T cell-mediated killing
- Disrupting the SLAMF6 interaction in tumour models with Lead Biologics’ candidate antibody LB-116, triggering a potent anti-cancer immune response and informing therapeutic strategies
12:15 pm Presentation by LIDE
12:45 pm Modeling Melanoma Resistance: Using Tumour Models to Validate JJP-1008 mAb Targeting CD160 & CD272
Synopsis
- Identifying CD160 and CD272 as key contributors to melanoma resistance in preclinical models, highlighting their clinical relevance in tumour immune evasion
- Demonstrating JJP-1008 as the first selective CD270 inhibitory signal-blocking IgG4 mAb, showing promising potential in overcoming melanoma resistance in model systems
- Showing through preclinical studies that JJP-1008 induces the shedding of LIGHT (CD258), offering new insights into the HVEM pathway and its potential for enhancing immunotherapy efficacy in melanoma models
1:15 pm Lunch & Networking
Leveraging Personalised Tumour Models to Better Predict Treatment Responses & Enhance Targeted Drug Development
2:15 pm Preclinical Development of BI-1206 -Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy
Synopsis
- Unveiling the development of a PDX-model that recapitulates relapsed/refractory disease
- Highlighting the importance of a relevant tolerability model for successful clinical development
2:45 pm Practical Applications of Tumour Models in ADC Development for Underserved Cancers
Synopsis
- Leveraging CDX, PDX, and in-house models to optimize ADC target expression and efficacy studies
- Translating preclinical tumour model data into predictive PK and dosing strategies for underserved cancer indications
- Addressing real-world challenges in tumour model applications with insights from brain tumour research
3:15 pm Poster Session & Refreshments Break
Synopsis
Witness some of the latest and greatest research in the tumour models field by drug developers, academics, and researchers in this spotlight poster session
4:00 pm Modeling Target/Receptor Axis for T Cell Therapy: Scalable Personalised TCR-T
Synopsis
- Development of engineered cancer cells for precise and systematic models to qualitatively map HLA-peptide targets
- Development of engineered T-cells for systematic determination of HLA-peptide target specific TCR activity
- Standardization of cell-based analysis platforms facilitating personalised treatment strategies
4:30 pm Tumour-like Conditions Enable the Development of Selective GCN2 Inhibitors
Synopsis
- Revealing nutrient deprivation in solid tumours, such as limited access to essential amino acids (AAs) in their microenvironment, which is crucial for understanding tumour metabolism and survival mechanisms in model systems
- Mimicking tumour-like conditions in preclinical models to identify vulnerabilities within the tumour microenvironment, enabling the discovery of novel therapeutic targets like GCN2
- Developing GCN2 inhibitors under these conditions, showing promising potential for selectively targeting tumour-specific stress pathways and offering new avenues for targeted cancer therapies